Fidelis Capital Partners LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Fidelis Capital Partners LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,399 shares of the medical device company’s stock, valued at approximately $187,000.

Several other institutional investors have also recently made changes to their positions in the stock. Forvis Mazars Wealth Advisors LLC raised its position in shares of DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock worth $1,359,000 after buying an additional 118 shares in the last quarter. Principal Securities Inc. raised its position in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after buying an additional 135 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares in the last quarter. GPS Wealth Strategies Group LLC raised its position in shares of DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after buying an additional 185 shares in the last quarter. Finally, Peterson Wealth Services raised its position in shares of DexCom by 7.1% in the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after buying an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 0.6 %

Shares of NASDAQ:DXCM opened at $81.96 on Thursday. The stock’s 50-day moving average price is $84.90 and its 200-day moving average price is $76.94. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market capitalization of $32.03 billion, a P/E ratio of 57.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DXCM. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Finally, Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 over the last ninety days. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.